Dabigatran eller warfarin vid elkonvertering i Region Skåne? – En kostnadsminimeringsanalys
Background: Dabigatran has been proved a valid medical substitute to warfarin in stroke preventing treatment of patients with atrial fibrillation. But cost-effectiveness analyses have shown that dabigatran, in comparison to warfarin, is not cost-effective at its current price. However, no existing studies are made in relation to cardio version. The object of this study was thus to evaluate whether
